Published in

Oxford University Press, Clinical Infectious Diseases, 4(73), p. e1008-e1010, 2021

DOI: 10.1093/cid/ciab086

Links

Tools

Export citation

Search in Google Scholar

Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial

Journal article published in 2021 by Toby Pepperrell, Willem Daniel Francois Venter ORCID, Kaitlyn McCann, Bronwyn Bosch, Melissa Tibbatts, Joanna Woods, Simiso Sokhela, Celicia Serenata, Michelle Moorhouse, Ambar Qavi, Andrew Hill
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Following evidence of HIV RNA re-suppression on DTG-based regimens, we assess the re-suppressive capacity of ADVANCE participants on TAF/FTC+DTG, TDF/FTC+DTG, and TDF/FTC/EFV. Viraemic participants were able to re-suppress within 3 follow-up visits of protocol-defined virological failure (PDVF) in 77/121 (64%), 85/126 (67%), and 44/138 (32%) cases respectively (DTG regimens vs. TDF/FTC/EFV; P < 0.001).